Somatostatin analogues in the anti-proliferative treatment of well-differentiated grade 2 NETs with Ki-67 ≥ 10% – Experience of an Algerian center

#3616

Introduction: Since the results of the CLARINET study, somatostatin analogues (SSAs) have an important place in the anti-proliferative treatment of well-differentiated neuroendocrine tumors (w-d NETs) grade 1 and 2 Ki-67<10%.

Aim(s): Evaluating the efficacy of SSAs in the anti-proliferative treatment of w-d NETs grade 2 Ki-67 ≥10%.

Materials and methods: Retrospective study of 16 patients (pts) diagnosed with w-d NETs grade 2 Ki-67 ≥10% treated with first line SSAs at the medical oncology department of Beni Messous University Hospital Center in Algiers, Algeria.

Conference:

Presenting Author: Belabdi D

Authors: Belabdi D, Chouki S, Yala I, Oukkal M,

Keywords: Well-differentiated NET, Grade 2 Ki-67≥10%, Somatostatin Analogues, Anti-proliferative treatment,